Samjin Pharmaceuticals Co., Ltd.

KSE 005500.KS

Samjin Pharmaceuticals Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 203.80 M

Samjin Pharmaceuticals Co., Ltd. Shareholders' Equity is USD 203.80 M for the year ending December 31, 2023, a -6.31% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Samjin Pharmaceuticals Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 217.52 M, a 10.98% change year over year.
Samjin Pharmaceuticals Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 196.00 M, a 0.02% change year over year.
Samjin Pharmaceuticals Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 195.95 M, a 15.12% change year over year.
Samjin Pharmaceuticals Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 170.22 M, a -7.26% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

KSE: 005500.KS

Samjin Pharmaceuticals Co., Ltd.

CEO	Yong-Joo Choi
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	121 Wausan Ro
Employees	586
Sector	Healthcare
Industries Biotechnology Clinical Trials Cosmetics Dental Care Eyewear Personal Care Pharmaceuticals Vaccines

Description

Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of cancer; SPJ1604 and SPJ003 clinical phase products for the treatment of cancer and diabetes; and SJP1901, SJP1902, SJP1801, and SJP006 biological testing stage products for the treatment of cancer, fibrosis, cancer immunotherapy, alzheimer's disease, Parkinson's disease, and anti-viral disease. The company was founded in 1968 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years